Lexaria Bioscience Secures IRB Approval for Five-Week DHT-Semaglutide Study Against Wegovy
LEXX•Lexaria Bioscience received IRB approval to initiate a five-week Human Pilot Study #7 evaluating two oral DehydraTECH-semaglutide formulations against Wegovy tablets, featuring tablet and capsule SNAC-inclusive compositions. Third-party QC testing of test articles completes in early June ahead of mid-June dosing.
1. IRB Approval and Study Objective
Lexaria Bioscience has secured independent ethics board approval to begin its five-week Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide compositions against marketed Wegovy tablets, with the primary goal of assessing safety, tolerability and pharmacokinetic performance.
2. Formulation and Study Design
The trial features a three-arm parallel group design under fasted pre-dose conditions, comparing SNAC-inclusive DehydraTECH semaglutide tablets and capsules to Wegovy, and incorporates tablet adhesion and dissolution enhancements modeled on existing oral semaglutide formulations.
3. Timeline and Funding
Laboratory formulation, commercial-scale manufacturing and third-party quality control testing will finish by early June, with packaging running in parallel and human dosing set to start in mid-June, all funded from existing corporate resources.
4. Commercial Collaboration Potential
Should the study demonstrate matched or superior pharmacokinetic results alongside strong safety and tolerability, Lexaria aims to leverage these data to secure pharmaceutical collaborations for its patented DehydraTECH oral delivery technology.
